Predisposing Factors for Coronary Vasospasm in Prinzmetal Angina - A Literature Review
DOI:
https://doi.org/10.12775/QS.2025.41.60317Keywords
Prinzmetal angina, angina pectoris, risk factors for angina pectorisAbstract
Introduction and Purpose: Prinzmetal angina or vasospastic angina (VSA) is cardiac ischemia caused by spasm of the coronary arteries. It is characterized by chest pain at rest and ST-segment elevation on electrocardiographic (ECG). Vasospasm can be focal or diffuse, but VSA often remains undiagnosed. The purpose of this study is to present risk factors for coronary vasospasm in Prinzmetal angina based on the available literature.
Materials and Methods: A literature review was conducted from the PubMed database, covering studies from 2015-2025. Meta-analyses and randomized controlled trials were analyzed. Key phrases such as “Prinzmetal angina,” “risk factors” and “angina pectoris” were used. Selected papers were evaluated for results and conclusions.
Description of the State of Knowledge: Symptoms of VSA include recurrent chest pain, relieved by nitrates. They occur at rest, mainly at night. VSA can be asymptomatic, leading to arrhythmias or sudden cardiac death. Diagnosis requires criteria, including confirmation of coronary artery spasm with more than 90% stenosis, observed during provocative testing.
Conclusions: VSA is associated with genetic and environmental factors, such as smoking, hyperthyroidism and chronic inflammation. Despite its coexistence with coronary artery disease, its presence does not always negatively affect prognosis. Further research may contribute to better diagnosis and personalization of therapy.
References
1. Picard F, Sayah N, Spagnoli V, Adjedj J, Varenne O. Vasospastic angina: A literature review of current evidence. Arch Cardiovasc Dis. 2019 Jan;112(1):44-55. doi: 10.1016/j.acvd.2018.08.002. Epub 2018 Sep 7. PMID: 30197243.
2. He Z, Xu X, Zhao Q, Ding H, Wang DW. Vasospastic angina: Past, present, and future. Pharmacol Ther. 2023;249:108500. doi:10.1016/j.pharmthera.2023.108500
3. Jenkins K, Pompei G, Ganzorig N, Brown S, Beltrame J, Kunadian V. Vasospastic angina: a review on diagnostic approach and management. Ther Adv Cardiovasc Dis. 2024;18:17539447241230400. doi:10.1177/17539447241230400
4. Sinha A, Rahman H, Perera D. Vasospastic Angina: A Contemporary Review of its Pathophysiology, Diagnosis and Management. Heart Int. 2022;16(2):99-104. Published 2022 Jul 26. doi:10.17925/HI.2022.16.2.99
5. Sheth MA, Widmer RJ, Dandapantula HK. Pathobiology and evolving therapies of coronary artery vasospasm. Proc (Bayl Univ Med Cent). 2021;34(3):352-360. Published 2021 Apr 21. doi:10.1080/08998280.2021.1898907
6. Harris JR, Hale GM, Dasari TW, Schwier NC. Pharmacotherapy of Vasospastic Angina. J Cardiovasc Pharmacol Ther. 2016;21(5):439-451. doi:10.1177/1074248416640161
7. Ricci F, Banihashemi B, Pirouzifard M, et al. Familial risk of vasospastic angina: a nationwide family study in Sweden. Open Heart. 2023;10(2):e002504. Published 2023 Dec 6. doi:10.1136/openhrt-2023-002504
8. Hikino K, Koyama S, Ito K, et al. RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction. JAMA Cardiol. 2024;9(8):723-731. doi:10.1001/jamacardio.2024.1483
9. Ishiyama H, Tanaka T, Yoshimoto T, et al. RNF213 p.R4810K Variant Increases the Risk of Vasospastic Angina. JACC Asia. 2023;3(5):821-823. Published 2023 Jun 27. doi:10.1016/j.jacasi.2023.05.002
10. Tran MV, Marceau E, Lee PY, Chandy M, Chen IY. The Smoking Paradox: A Twist in the Tale of Vasospastic Angina. J Vasc Med Surg. 2021;9(7):438.
11. Kim HJ, Jo SH, Lee MH, Seo WW, Baek SH. Hyperthyroidism Is Associated with the Development of Vasospastic Angina, but Not with Cardiovascular Outcomes. J Clin Med. 2020;9(9):3020. Published 2020 Sep 19. doi:10.3390/jcm9093020
12. Hung MY, Hung MJ. Relationship between Inflammation and Vasospastic Angina. Medicina (Kaunas). 2023;59(2):318. Published 2023 Feb 9. doi:10.3390/medicina59020318
13. Kim DY, Kim SE, Park TK, et al. Elevated white blood cell count and long-term clinical outcomes of patients with vasospastic angina. Coron Artery Dis. 2024;35(5):382-388. doi:10.1097/MCA.0000000000001359
14. Oumi T, Nozato T, Sakakibara A, et al. Malondialdehyde-Modified Low Density Lipoprotein as Oxidative-Stress Marker in Vasospastic Angina Patients. Int Heart J. 2017;58(3):335-343. doi:10.1536/ihj.16-455
15. Teragawa H, Uchimura Y, Oshita C, Hashimoto Y, Nomura S. Frequency and Clinical Impact of Family History of Coronary Artery Disease in Patients with Vasospastic Angina. J Cardiovasc Dev Dis. 2023;10(6):249. Published 2023 Jun 8. doi:10.3390/jcdd10060249
16. Saito Y, Saito Y, Kato K, Kobayashi Y. Gender differences in factors associated with vasospastic angina. Int J Cardiol. 2022;349:7-11. doi:10.1016/j.ijcard.2021.11.047
17. Choi BG, Lee J, Kim SW, et al. The association of chronic air pollutants with coronary artery spasm, vasospastic angina, and endothelial dysfunction. Coron Artery Dis. 2018;29(4):336-343. doi:10.1097/MCA.0000000000000603
18. Boudou N, Despas F, Rothem JV, et al. Direct evidence of sympathetic hyperactivity in patients with vasospastic angina. Am J Cardiovasc Dis. 2017;7(3):83-88. Published 2017 Jun 15.
19. Asada K, Saito Y, Takaoka H, Kitahara H, Kobayashi Y. Relation of Perivascular Adipose Tissues on Computed Tomography to Coronary Vasospasm. Rev Cardiovasc Med. 2025;26(2):26327. Published 2025 Feb 18. doi:10.31083/RCM26327
20. Matsumoto T, Saito Y, Saito K, et al. Relation Between Cancer and Vasospastic Angina. Adv Ther. 2021;38(8):4344-4353. doi:10.1007/s12325-021-01854-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Znamirowska, Klaudia Mularczyk, Monika Paszkowska, Łukasz Karaban, Magdalena Kupis, Anna Jakubiak, Joanna Miśkiewicz, Michał Borawski, Aleksandra Ciuła, Tadeusz Kuźnieców

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 122
Number of citations: 0